Literature DB >> 15141325

Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines.

Toshio Sasajima1, Tadashi Miyagawa, Takamitsu Oku, Juri G Gelovani, Ronald Finn, Ronald Blasberg.   

Abstract

Amino acid imaging is increasingly being used for assessment of brain tumor malignancy, extent of disease, and prognosis. This study explores the relationship between proliferative activity, amino acid transport, and glucose metabolism in three glioma cell lines (U87, Hs683, C6) at different phases of growth in culture. Growth phase was characterized by direct cell counting, proliferation index determined by flow cytometry, and [(3)H]thymidine (TdR) accumulation, and was compared with the uptake of two non-metabolized amino acids ([(14)C]aminocyclopentane carboxylic acid (ACPC) and [(14)C]aminoisobutyric acid (AIB)), and [(18)F]fluorodeoxyglucose (FDG). Highly significant relationships between cell number (density), proliferation index, and TdR accumulation rate were observed in all cell lines ( r>0.99). Influx ( K(1)) of both ACPC and AIB was directly related to cell density, and inversely related to the proliferation index and TdR accumulation in all cell lines. The volume of distribution ( V(d)) for ACPC and AIB was lowest during rapid growth and highest during the near-plateau growth phase in all cell lines. FDG accumulation in Hs683 and C6 cells was unaffected by proliferation rate, growth phase, and cell density, whereas FDG accumulation was correlated with TdR accumulation, growth phase, and cell density in U87 cells. This study demonstrates that proliferation rate and glucose metabolism are not necessarily co-related in all glioma cell lines. The values of K(1) and V(d) for ACPC and AIB under different growth conditions suggest that these tumor cell lines can up-regulate amino acid transporters in their cell membranes when their growth conditions become adverse and less than optimal.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15141325     DOI: 10.1007/s00259-004-1512-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  51 in total

1.  TA1/LAT-1/CD98 light chain and system L activity, but not 4F2/CD98 heavy chain, respond to arginine availability in rat hepatic cells. Loss Of response in tumor cells.

Authors:  W A Campbell; D E Sah; M M Medina; J E Albina; W B Coleman; N L Thompson
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

2.  Differential influence of cAMP on the expression of the three subtypes (ATA1, ATA2, and ATA3) of the amino acid transport system A.

Authors:  T Hatanaka; W Huang; R G Martindale; V Ganapathy
Journal:  FEBS Lett       Date:  2001-09-14       Impact factor: 4.124

3.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

4.  Comparison of trypan blue dye exclusion and fluorometric assays for mammalian cell viability determinations.

Authors:  S A Altman; L Randers; G Rao
Journal:  Biotechnol Prog       Date:  1993 Nov-Dec

5.  FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models.

Authors:  U Haberkorn; S I Ziegler; F Oberdorfer; H Trojan; D Haag; P Peschke; M R Berger; A Altmann; G van Kaick
Journal:  Nucl Med Biol       Date:  1994-08       Impact factor: 2.408

6.  Clinical value of iodine-123-alpha-methyl-L-tyrosine single-photon emission tomography in the differential diagnosis of recurrent brain tumor in patients pretreated for glioma at follow-up.

Authors:  Samuel Samnick; Jochen B Bader; Dirk Hellwig; Jean Richard Moringlane; Christof Alexander; Bernd F M Romeike; Wolfgang Feiden; Carl-Martin Kirsch
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

7.  Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study.

Authors:  Mei Tian; Hong Zhang; Yoshiki Nakasone; Kenji Mogi; Keigo Endo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-10       Impact factor: 9.236

8.  Positron emission tomography and computed tomography in differential diagnosis between recurrent or residual glioma and treatment-induced brain lesions.

Authors:  A Lilja; H Lundqvist; Y Olsson; B Spännare; P Gullberg; B Långström
Journal:  Acta Radiol       Date:  1989 Mar-Apr       Impact factor: 1.990

9.  Comparison of the accumulation kinetics of L-(methyl-11C)-methionine and D-(methyl-11C)-methionine in brain tumors studied with positron emission tomography.

Authors:  M Bergström; H Lundqvist; K Ericson; A Lilja; P Johnström; B Långström; H von Holst; L Eriksson; G Blomqvist
Journal:  Acta Radiol       Date:  1987 May-Jun       Impact factor: 1.990

10.  Aging effect on neutral amino acid transport at the blood-brain barrier measured with L-[2-18F]-fluorophenylalanine and PET.

Authors:  H Ito; J Hatazawa; M Murakami; S Miura; H Iida; P M Bloomfield; I Kanno; H Fukuda; K Uemura
Journal:  J Nucl Med       Date:  1995-07       Impact factor: 10.057

View more
  12 in total

Review 1.  Non-invasive metabolic imaging of brain tumours in the era of precision medicine.

Authors:  Michelle M Kim; Abhijit Parolia; Mark P Dunphy; Sriram Venneti
Journal:  Nat Rev Clin Oncol       Date:  2016-07-19       Impact factor: 66.675

2.  Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy.

Authors:  Johannes Schwarzenberg; Johannes Czernin; Timothy F Cloughesy; Benjamin M Ellingson; Whitney B Pope; Tristan Grogan; David Elashoff; Cheri Geist; Daniel H S Silverman; Michael E Phelps; Wei Chen
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

3.  Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines.

Authors:  Burkhard Riemann; Otmar Schober
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03       Impact factor: 9.236

Review 4.  Molecular imaging of gliomas with PET: opportunities and limitations.

Authors:  Christian la Fougère; Bogdana Suchorska; Peter Bartenstein; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn
Journal:  Neuro Oncol       Date:  2011-07-13       Impact factor: 12.300

Review 5.  Switching on the lights for real-time multimodality tumor neuroimaging: The integrated positron-emission tomography/MR imaging system.

Authors:  S Bisdas; T Nägele; H-P Schlemmer; A Boss; C D Claussen; B Pichler; U Ernemann
Journal:  AJNR Am J Neuroradiol       Date:  2009-11-26       Impact factor: 3.825

6.  [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence.

Authors:  S Ceyssens; K Van Laere; T de Groot; J Goffin; G Bormans; L Mortelmans
Journal:  AJNR Am J Neuroradiol       Date:  2006-08       Impact factor: 3.825

Review 7.  11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas.

Authors:  Tarun Singhal; Tanjore K Narayanan; Viney Jain; Jogeshwar Mukherjee; Joseph Mantil
Journal:  Mol Imaging Biol       Date:  2007-10-24       Impact factor: 3.488

8.  Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage.

Authors:  Morten Busk; Michael R Horsman; Steen Jakobsen; Johan Bussink; Albert van der Kogel; Jens Overgaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-06       Impact factor: 9.236

9.  Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography.

Authors:  A Pal; A Glekas; M Doubrovin; J Balatoni; Mohammed Namavari; T Beresten; D Maxwell; S Soghomonyan; A Shavrin; L Ageyeva; R Finn; S M Larson; W Bornmann; J G Gelovani
Journal:  Mol Imaging Biol       Date:  2006 Sep-Oct       Impact factor: 3.484

10.  Synthesis, Radiolabeling and Biological Evaluation of (99m)Tc-labeled Deoxyglucose Derivatives for Molecular Imaging.

Authors:  Masoud Sadeghzadeh; Ghorbanali Charkhlooiea; Fariba Johari Daha
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.